A SAFETY, TOLERABILITY AND IMMUNOGENICITY STUDY OF 2 DIFFERENT REGIMENS OF TETRAVALENT AD26.MOS4.HIV PRIME FOLLOWED BY BOOST WITH TETRAVALENT AD26.MOS4.HIV ALONG WITH EITHER CLADE C GP140 PLUS ADJUVANT OR WITH A COMBINATION OF MOSAIC AND CLADE C GP140 PLUS ADJUVANT IN HEALTHY HIV UNINFECTED ADULTS: